(Q42981515)

English

Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa

scientific article published on November 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 November 2017

Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa (English)

1 reference

Europe PubMed Central

12 November 2017

1 reference

based on heuristic

inferred from title

Hepatitis C virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

7

object named as

Mark S Sulkowski

1 reference

Europe PubMed Central

12 November 2017

author name string

Douglas T Dieterich

1

1 reference

Europe PubMed Central

12 November 2017

Ronald Wasserman

2

1 reference

Europe PubMed Central

12 November 2017

Norbert Bräu

3

1 reference

Europe PubMed Central

12 November 2017

Tarek I Hassanein

4

1 reference

Europe PubMed Central

12 November 2017

Edmund J Bini

5

1 reference

Europe PubMed Central

12 November 2017

Peter J Bowers

6

1 reference

Europe PubMed Central

12 November 2017

language of work or name

0 references

publication date

1 November 2003

1 reference

Europe PubMed Central

12 November 2017

The American Journal of Gastroenterology

1 reference

Europe PubMed Central

12 November 2017

98

1 reference

Europe PubMed Central

12 November 2017

11

1 reference

Europe PubMed Central

12 November 2017

2491-2499

1 reference

Europe PubMed Central

12 November 2017

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.08700.X

21 January 2018

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.08700.X

21 January 2018

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.08700.X

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.08700.X

21 January 2018

Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.08700.X

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.08700.X

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.08700.X

21 January 2018

Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.08700.X

21 January 2018

Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.08700.X

21 January 2018

Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.08700.X

21 January 2018

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.08700.X

21 January 2018

Epoetin alfa therapy for anaemia in HIV-infected patients: impact on quality of life

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.08700.X

21 January 2018

Anemia and survival in HIV infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.08700.X

21 January 2018

A preliminary study of erythropoietin for anemia associated with ribavirin and interferon-alpha

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2003.08700.X

21 January 2018

Identifiers

10.1111/J.1572-0241.2003.08700.X

1 reference

Europe PubMed Central

12 November 2017

release_66pjxvde25f4vb5vf2kjwzn7fm

1 reference

https://api.fatcat.wiki/v0/release/66pjxvde25f4vb5vf2kjwzn7fm

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42981515&oldid=1975637139"